PremiumHealthcare Finance & M&A
Lilly's Retatrutide Clears Phase 3 Obesity Hurdles but Cardiovascular Benefit Remains Unproven
The triple-G agonist achieved 22.6% weight loss in phase 3 trials, yet failed to confirm the cardiovascular risk reduction investors had anticipated.
VanadiumNews Research Team · 5 min · 26 Jul 2026